In recent years we have refocused our efforts and invested heavily in the UK—our new global headquarters in Cambridge is just one example— and we want…
In Conversation
"Our products are dispensed to fulfil over 1 in 6 generic prescriptions in the UK, meaning probably everyone in the UK has taken one of our…
" It is a very competitive scene out there, regardless of Brexit. Everything creates competition, globalization makes it more competitive for London, for talent and capital.…
"Many GPs also systematically refer patients when unsure about an ophthalmologic condition, which means that many people are referred into hospitals that should not be."
"The new, focused strategy equips us to build on our CNS heritage and expertise, remain patient-focused and meet current health needs here in the UK"
"Historically, many British biotechnology companies have been acquired or sold their product(s) early in their existence. Immunocore will launch its first product in the ultra-rare disease…
While the UK may represent a relatively small percentage of overall global sales, our virtual impact is much bigger
"Otsuka has a smart strategy: it will never bring to market a ‘me too’ product. Aligned with our global mission of truly improving healthcare, we focus…
"We believe that the future is going to be populated not just by large companies but also by coalitions of smaller companies. There will be a…
"[Brexit] presents an opportunity for the UK to improve its environment for life sciences"
In the end, no matter what political commentators or economists say, the UK will remain a top six or five economy globally, and in any scenario,…
"We continue to work very closely with pharma partners to deliver benefits to patients. Together we focus not only on new drugs but on lifestyle changes…
